

DAFTAR PUSTAKA

- Abdullah, N., Abo E.W.H., Allam, A.A. and Mohamed, A.M. (2018). Aberrant expression of CD markers in cases with acute leukemia in Sohag University Hospital. *Sohag Medical Journal* 22: 287–295.
- Ahmad, N, Kumari, N, Tirkey, D, Mahto, S.K, Jawaid, M. (2024). Evaluation of Acute Leukaemias by Flow Cytometry and Its Correlation With Diagnosis Using Morphological and Special Staining Techniques. *Cureus*. 13;16(2):e54126. doi: 10.7759/cureus.54126.
- Alkayed, K., Khattab, E. and Madanat, F. (2015). Aberrant T-cell antigen expression in Jordanian children with B lymphoblastic leukemia. *Hematology/Oncology and Stem Cell Therapy*. 8: 187–188.
- Aparna, S.K. and Sharmilla, M. (2018). Aberrant phenotypes in acute myeloid leukaemia in India. *International Journal of Advances in Medicine* 5: 361–365.
- Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., *et al.*, (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 127(20): 2391–2405.
- Aryati, Triyono, T., Hartini, S., Ludong, M.M., Tambunan, B.A. and Kosasih, A.S. (2022). *Pedoman Nasional Penggunaan Flowsitometri pada Diagnosis Leukemia Akut*. Jakarta: Perhimpunan Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium Indonesia (PDS PatKLIIn). Available at: https://www.pdspatklin.or.id/assets/files/pdspatklin_2023_06_05_14_55_23.pdf (Accessed: 13 November 2025).
- Bain, B.J. (2001). Bone marrow aspiration. *Journal of Clinical Pathology*. 54(9): 657–663.
- Bain, B.J. and Swirsky, D. (2012). Sudan black B is a lipophilic dye that stains the granulocytic series. In: Bain, B.J., Bates, I., Laffan, M.A. and Lewis, S.M. (eds.) *Dacie and Lewis Practical Haematology*. 11th ed. Churchill Livingstone: 333–352.
- Basharat, M., Khan, S.A., Din, N.U. and Ahmed, D. (2019). Immunophenotypic characterisation of morphologically diagnosed cases of acute myeloid leukaemia (AML). *Pak J Med Sci*. 35: 470–476.
- Batinić, D., Tindle, R., Boban, D., Tiefenbach, A., Rajić, L., Labar, B., *et al.*, (1989). Expression of haematopoietic progenitor cell-associated antigen BI-3C5/CD34 in leukemia. *Leukemia Research* 13(1): 83–85.

- BD Biosciences (2025). *BD OneFlow™ ALOT* [online]. Available at: <https://www.bdbiosciences.com>
- Belurkar, S., Mantravadi, H., Manohar, C., Kurien, A. (2013). Correlation of morphologic and cytochemical diagnosis with flowcytometric analysis in acute leukemia. *J Cancer Res Ther.* 9(1): 71–79.
- Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. *et al.*, EGIL (1995). Proposals for the immunological classification of acute leukemias. *Leukemia.* 9(10): 1783–1786.
- Béné, M.C. (2005). Immunophenotyping of acute leukaemias. *Immunology Letters* 98(1): 9–21.
- Bidikian, A, Bewersdorf, J.P, Kewan, T, Stahl, M, Zeidan, A.M. (2024). Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. *Cancers (Basel).* 16(23): 4092. doi: 10.3390/cancers16234092.
- Bonnet, D. and Dick, J.E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nature Medicine* 3(7): 730–737.
- Bras, A.E, Osmani, Z, de Haas V, Jongen-Lavrencic M, Te Marvelde, J.G, Zwaan, C.M. (2021). Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia. *Br J Haematol.*193(5):922-927. doi: 10.1111/bjh.17210.
- Carr, J.H. and Rodak, B.F. (2019). *Clinical Hematology Atlas.* 5th ed. St. Louis: Elsevier: 11.
- Charles, N.J. and Boyer, D.F. (2017). *Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls.* *Archives of Pathology & Laboratory Medicine*, 141(11): 1462–1468.
- Chen, J, Pang, W, Deng, M, Zheng, R, Chen, Y, Zhang, Z. (2025). Global, regional, and national burden of leukemia, 1990–2021: a systematic analysis of the global burden of disease in 2021. *Front Med.* 12: 1542317. doi:10.3389/fmed.2025.1542317.
- Chennamadhavuni, A., Iyengar, V., Mukkamalla, S.K.R., Shimanovsky, A. (2023) Leukemia. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing.

- Chien, L.N., Tzeng, H.E., Liu, H.Y., Chou, W.C., Tien, H.F. and Hou, H.A. (2023). Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: A national population-based analysis from 2001 to 2015. *Journal of the Formosan Medical Association* 122(6): 505–513.
- Cohen J,A. (1960). coefficient of agreement for nominal scales. *Educational and Psychological Measurement*. 20(1):37–46
- Cui W, Zhang D, Cunningham MT, Tilzer L. (2014). Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings. *Int J Lab Hematol*. 36(6): 636-49.
- Döhner, H, Estey, E, Grimwade, D, Amadori, S, Appelbaum, FR, Büchner, T, *et al.* (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 129(4): 424–447.
- Dores, G.M., Devesa, S.S., Curtis, R.E., Linet, M.S., Morton, L.M. (2012). Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. *Blood*. 119: 34–43. doi: 10.1182/blood-2011-04-347872.
- Dworzak, M.N., Buldini, B., Gaipa, G., Ratei, R., Hrusak, O., Luria, D., *et al.* (2018). AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia. *Cytometry Part B*. 94B: 82–93.
- Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, *et al.*, (2021). Cancer statistics for the year 2020: An overview. *Int J Cancer*. 5(1): 1 doi: 10.1002/ijc.33588.
- Francis J, Dharmadhikari AV, Sait SN, Deeb G, Wallace P.K, Thompson J.E, *et al.*, (2013). CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. *Leuk Lymphoma*. 4(7) : 1517-20. doi: 10.3109/10428194.2012.754096
- Frederiks, W.M. (1977). Some aspects of the value of Sudan Black B in lipid histochemistry. *Histochemistry*. 54(1): 27–37.
- Gupta, R., Kaul, K.K. and Dewan, D. (2015). Clinicomorphological profile in acute leukemias: Experience from a tertiary care centre in Jammu. *Indian J Res*. 4: 4–6.

- Hamid, G.A. (2011). Classification of acute leukemia. In: M.M. Mueser (ed.) *Acute Leukemia – The Scientist’s Perspective and Challenge*. Rijeka: InTech, pp.3–28.
- Hendricks, C.L., Jacobs, P. and Wainwright, H. (2017). Comparing morphology, flow cytometry and molecular methods for minimal residual disease detection in leukaemia. *South African Journal of Oncology*. 1(1):1–9.
- Henry, J.B. (2011). *Clinical Diagnosis and Management by Laboratory Methods*. 22nd ed. Philadelphia: Saunders Elsevier.
- Heo, S.K., Noh, E.K., Ju, L.J., Sung, J.Y., Jeong, Y.K., Cheon, J. *et al.* (2020) CD45dim CD34+ CD38– CD133+ cells have the potential as leukemic stem cells in acute myeloid leukemia, *BMC Cancer*, 20: 285. Available at: <https://doi.org/10.1186/s12885-020-06760-1>
- Hoffbrand, A.V. and Moss, P.A.H. (2016) *Essential Haematology*. 7th ed. Wiley-Blackwell.
- Hoffman, R., Benz, E.J., Silberstein, L.E. Abutalib S.A *et al.* (2018). *Hematology: Basic Principles and Practice*. 7th edn. Philadelphia: Elsevier.
- Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M *et al.* (2019) *SEER Cancer Statistics Review, 1975–2017: Childhood cancer*. Bethesda, MD: National Cancer Institute. Available at: <https://seer.cancer.gov/csr/1975/> (Accessed: 13 November 2025).
- Humayun, M., Khan, S.A. and Muhammad, W. (2005). Investigation on the prevalence of leukemia in North West Frontier Province of Pakistan. *Trop J Cancer*. 35(3): 119–122.
- Inaba, H. and Mullighan, C.G. (2020). Genetic basis of acute lymphoblastic leukemia. *Journal of Clinical Oncology* 38(30): 3366–3378.
- Itonaga H, Imanishi D, Wong Y.F, Sato S, Ando K, Sawayama Y, *et al.* (2014). Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B. *Leukemia* 28: 1459–1466.
- Jaffe, E.S., Arber, D.A., Campo, E., Harris, N.L. and Quintanilla-Martinez, L. (2022). *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. 5th ed. Lyon: International Agency for Research on Cancer (IARC): 9–21.

- Jensen, K.C., Higgins, J.P.T., Montgomery, K., Kaygusuz, G., van de Rijn, M. and Natkunam, Y. (2007). The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms. *Modern Pathology*, 20(8): 871–877.
- Juliusson, G., Lehmann, S. and Lazarevic, V. (2021). Epidemiology and etiology of AML. In: Röllig, C. and Ossenkoppele, G.J. (eds.) *Acute Myeloid Leukemia*. Hematologic Malignancies. Cham: Springer, pp.148–171.
- Kementerian Kesehatan Republik Indonesia. (2019). *Riset Kesehatan Dasar (Riskesdas) 2018*. Jakarta: Kemenkes RI.
- Khan, M, Din, M, Naeem, Z, Sajid, Z, Khan, D, Amjad, *et al.*, (2020). Insights into Acute Myeloid Leukemia: Critical Analysis on its Wide Aspects. *Abasyn Journal of Life Sciences* 3(2): 1-9.
- Khoury, J.D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J.F., *et al.* (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*, 36: 1703–1719.
- Kosasih, A.S., Setiawan, L., Hartini, S.I. (2010). Immunophenotyping in the diagnosis and classification of acute leukemia: Dharmais Cancer Hospital experience. *Indones J Cancer*. 5: 698–392.
- Ladines, C.W., Barragán I.G., Luna P.M.A., Santoyo S.A., Collazo J.J., Mendoza G.E. *et al.*, (2016). Morphology of leukaemias. *Revista Médica del Hospital General de México*, 79(2): 107–113.
- Long, N.A., Golla, U., Sharma, A. (2022). Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications. *Stem Cell Reviews and Reports*, 18: 1211–1226.
- Mangum D.S, Bishop J.D, Zhou Y, Cheng C, Karol S.E, Rubnitz J.E, *et al.*, (2023). Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis. *Br J Haematol*. 200(3):338-343. doi: 10.1111/bjh.18552.
- McPherson, R.A. and Pincus, M.R. (2017). *Henry's clinical diagnosis and management by laboratory methods*. 23rd ed. Elsevier.
- Mufti, G.J., Bennett, J.M., Goasguen, J., Bain, B.J., Baumann, I., Brunning, R., *et al.* (2008). Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. *Haematologica*. 93 : 1712–1717.

- Mulatsih S, Hariningrum A, Purwanto I. (2019). Implementing Yogyakarta Pediatric Cancer Registry for 16 Years: a report of hospital-based childhood cancer registry *Sri. Pediatr Indones.* 59(4):188–94.
- Mullighan, C.G. (2012). Molecular genetics of B-precursor acute lymphoblastic leukemia. *Journal of Clinical Investigation*, 122(10): 3407–3415.
- Munga, D., Githanga, J., Njuguna, F. and Kimani, Z. (2023). Comparison between Acute Leukemia Screening Tube and Lineage-Specific Panels for the Diagnosis of Acute Leukemia in Kenya, *African Journal of Laboratory Medicine*, 12(1), pp. 1–8.
- Naeim, F., Rao, P.N., Song, S.X. and Phan, R.T. (2018). Acute myeloid leukemia—overview. In: *Atlas of Hematopathology*. 2nd ed. Academic Press: 293–302.
- Nasim, N., Malik, K., Malik, N.K., Mobeen, S., Awan, S. and Mazhar, M. (2013). Investigation on the prevalence of leukemia at a tertiary care hospital, Lahore. *Biomedica*, 29: 19–22.
- Nurmalasari, S.A., Widjajanto, P.H., Mulatsih, S. and Purwanto, I. (2012). Leukemia myeloblastik akut: luaran terapi di RSUP Dr. Sardjito, Yogyakarta, 2004–2008. *Indonesian Journal of Cancer*, 6(2): 63–68.
- Nurunnabi, M., Mamdu, M.K., Siddika, A., Zafreen, F., Wahab, M.A. and Shermin, S. (2020). Morphological and immunophenotypic analysis in diagnosis of acute leukaemia. *Delta Medical College Journal*, 8(1): 15–20.
- Omman, R.A. and Kini, A.R. (2020) Acute leukemias. In: Keohane, E.M., Otto, C.N. and Walenga, J.M. (eds.) *Rodak's Hematology: Clinical Principles and Applications*. 6th ed. Elsevier, pp. 540–554.
- Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van L.P, *et al.* (2016). Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*, 128(5): 678–692.
- Parikh, B, Kumar, A, Trivedi, P, Jetly, D, Khanna, N, Thummar, S. (2017). Correlation between Morphology and Special Stains with Flow Cytometry in the Diagnosis of Acute Leukemia. *SJAMS*. 5(6A): 2047–2051.
- Patel, G.N, Gudur R, Gudur A, Oswal R.M, Kanethkar S. (2021). Clinicopathological Evaluation of Acute Leukemias in a Tertiary Care Hospital: A Cross-Sectional Study. *Turk Patoloji Derg.* 37(2):145-153.
- Percival, M.E., Lai, C., Estey, E. and Hourigan, C.S. (2017). Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. *Blood Reviews*, 31(4): 185–192.

- Perdana, A.B, Saputra, F., Aisyi, M., (2020). Update on Diagnosis of Childhood Acute Lymphoblastic Leukemia (ALL) in Indonesia. *Indones J Cancer*. 14(4): 115–116. DOI: <http://dx.doi.org/10.33371/ijoc.v14i4.818>
- Pinheiro, L.H.S., Trindade, L.D., Costa, F.O., Silva, N.L., Sandes, A.F., Nunes, M.A.P *et al.*, (2020). Aberrant phenotypes in acute myeloid leukemia and its relationship with prognosis and survival: a systematic review and meta-analysis. *Int J Hematol Oncol Stem Cell Res*. 14(4): 274–288.
- Pritchard, C.L., Heazlewood, S.Y. and Cao, B. (2021) *Acute lymphoblastic leukemia and the bone marrow microenvironment*. In: Nilsson, S. (ed.) *Advances in Stem Cells and their Niches*. Vol. 5. Elsevier, pp. 1–34. <https://doi.org/10.1016/bs.asn.2020.11.001>
- Pui C.H, Campana D, Pei D, Bowman W.P, Sandlund J.T, Kaste S.C, Ribeiro R.C, Rubnitz J.E, *et al.* (2009). Treating childhood acute lymphoblastic leukemia without cranial irradiation. *N Engl J Med*, 360(26) : 2730–2741.
- Pui C.H, Yang J.J, Bhakta N, Rodriguez-Galindo C. (2018). Global efforts toward the cure of childhood acute lymphoblastic leukemia. *Lancet Child Adolesc Heal*. 2(6):440–454.
- Qu X, Zheng A, Yang J, Zhang J, Qiao H, Jiang F, *et al.* (2024). Global, regional, and national burdens of leukemia from 1990 to 2019: a systematic analysis of the global burden of disease in 2019 based on the APC model. *Cancer Med*. 1:e7150. doi: 10.1002/cam4.7150
- Rahnemoon, A.R. (2022). Immunophenotyping investigation in acute and chronic leukemias as a gold standard test. *Cancer Res. Cell. Ther*. 6(1): 106.
- Rausei M.V, Chang K.L, Gaal K.K, Weiss L.M, Huang Q. (2008). Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. *Am J Clin Pathol*. 129(4):624–9. doi: 10.1309/NRTX9AKXHR5JBT93.
- Resende, G.A.D., Gileno, M.C., Moraes-Souza, H., Carlos, A.M., Leal, A.S. and Martins, P.R.J. (2017). The role of cytochemistry in the diagnosis of acute leukemias. *International Journal of Health Sciences & Research*.7(8): 290–295.
- Salem, A.K, Al-hag, A.Y, Aljaber, N, Al-Kadasy, W, Abdulrab, A, Hadi, A.A *et al.* (2020). Correlation of cyto-morphology with flow cytometric immunophenotyping in acute leukemia's: A Comparative study. *Hematol Blood Disord*. 3(2):1.

- Sarma, A., Hazarika, M., Das, D., Rai, A.K., Sharma, J.D., Bhuyan, C *et al.*, (2015). Expression of aberrant CD markers in acute leukemia: a study of 100 cases with immunophenotyping by multiparameter flowcytometry. *Cancer Biomarkers*. 15: 501–505.
- Shahni A, Saud M, Siddiqui S, Mukry SN. (2018). Expression of aberrant antigens in hematological malignancies:A single center experience. *Pak J Med Sci*. 34(2):457–462.
- Shallis, R.M., Wang, R., Davidoff, A., Ma, X. and Zeidan, A.M. (2019). Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. *Blood Reviews* 36: 70–87.
- Shrestha, S., Shrestha, J., Pun, C., Pathak, T., Bastola, S. and Bhatta, R. (2013). Immunophenotypic study of acute leukemia by flow cytometry at BPKMCH. *Journal of Pathology of Nepal*, 3(5): 345–350.
- Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022). Cancer statistics, 2022. *CA: A Cancer Journal for Clinicians*, 72(1): 7–33.
- Simanjorang C, Kodim N, Tehiteru E. (2013). Perbedaan kesintasan 5 tahun pasien leukemia limfoblastik akut dan leukemia mieloblastik akut pada anak di Rumah Sakit Kanker Dharmais, Jakarta, 1997-2008. *Indones J Cancer*. 7(1):15–21.
- Simmons, D.L., Satterthwaite, A.B., Tenen, D.G. and Seed, B. (1992). Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. *Journal of Immunology* 148(1): 267–271.
- Singh, G., Parmar, P., Kataria, S.P. (2016). Spectrum of acute and chronic leukaemia in tertiary care hospital, Haryana, India. *Int J Med Res Sci*. 4: 1115–1118.
- Siraki, A.G. (2021). The many roles of myeloperoxidase: from inflammation and immunity to biomarkers, drug metabolism and drug discovery. *Redox Biology*, 46: 102109.
- Strobl, H, Takimoto, M, Majdic, O, Fritsch, G, Scheinecker, C, Höcker, P *et al.* (1993). Myeloperoxidase expression in CD34+ normal human hematopoietic cells. *Blood*. 82: 2069.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. *et al.*, (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71: 209–249.

- Supriyadi, E., Widjajanto, P.H., Veerman, A.J.P., Purwanto, I., Nancy, Y.M., Gunawan, S., *et al.*. (2011). Immunophenotypic patterns of childhood acute leukemias in Indonesia. *Asian Pacific Journal of Cancer Prevention*, 12, pp. 3381–3387.
- Suzanna E, Sirait T, Rahayu PS, Shalmont, G, Anwar, E, Andalusia, R *et al.* (2007). Registrasi Kanker Berbasis Rumah Sakit di Rumah Sakit Kanker “Dharmais”– Pusat Kanker Nasional, 1993-2007. *Indones J Cancer*. 6(4):181–205.
- Swerdlow S.H, Campo E, Harris N.L, Jaffe E.S, Pileri S.A, Stein H *et al.*, (2017). *WHO classification of tumours of haematopoietic and lymphoid tissues*. 4th ed. Lyon: IARC.
- Tefferi, A. and Vardiman, J.W. (2009). Acute leukemia—A practical approach to diagnosis, *Mayo Clinic Proceedings*, 84(11): 947–958.
- Thomas, D. and Majeti, R. (2017). Biology and relevance of human acute myeloid leukemia stem cells. *Blood*, 129: 1577–1583.
- Tkachenko, A., Kupcova, K. and Havranek, O. (2024). B-Cell receptor signaling and beyond: the role of Igα (CD79a)/Igβ (CD79b) in normal and malignant B cells. *International Journal of Molecular Sciences*, 25(1): 10.
- Van Dongen, J.J., Krissansen, G.W., Wolvers-Tettero, I.L., Comans-Bitter, W.M., Adriaansen, H.J., Hooijkaas, H., *et al.*, (1988). Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. *Blood*, 71(3): 603–612.
- Wang, K., Wei, G. and Liu, D. (2012). CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. *Experimental Hematology & Oncology*, 1(1): 36.
- Wang, Y., Xiao, M., Chen, X., Chen, L., Liu, Q., Jin, J. *et al.* (2012). Coexpression of myeloid and lymphoid markers in acute leukemia: a high frequency of aberrant expression of CD19 in t(8;21) acute myeloid leukemia. *American Journal of Clinical Pathology*, 138(5): 733–738.
- Wibawa, I.M.B.C., Subawa, A.A.N., Yasa, I.W.P.S., Mahartini, N.N. (2021). Gambaran karakteristik pasien *acute myeloid leukemia* di RSUP Sanglah Denpasar tahun 2018, *Jurnal Medika Udayana*, 10(6):38–45. doi:10.24843/MU.2020.V10.i6.P08.
- Wolley, N.G.A, Gunawan, S, Warouw, S.M. (2016). Perubahan status gizi pada anak dengan leukemia limfoblastik akut selama pengobatan. *e-CliniC*. 4(1).

- Xu, X.Q., Wang, J.M., Lu, S.Q., Chen, L., Yang, J.M., Zhang, W.P *et al.*, (2009). Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. *Haematologica*. 94(7): 919–927.
- Zaini R.G, Nawwab W.A, Alharthi S, Alboqami N.F, Hazzazi S.A, Althubaity T.A, A *et al.*, (2025) The Prevalence and Characteristics of Anemia Among Newly-Diagnosed Patients with Leukemia in Saudi Arabia. *Clin Lab*. 71(4): 1 doi: 10.7754/Clin.Lab.2024.241002.
- Zeng, Z, Shi, Y.X, Samudio, I.J, Wang, R.Y, Ling, X, Frolova, O *et al.* (2021). Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. *Blood*. 137(22): 3132–3145.